Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Debate over H-1B visas shines spotlight on US tech worker shortages 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Yes, government influences wages – but not just in the way you might think 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated 
Why a ‘rip-off’ degree might be worth the money after all – research study 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
US Judge Dismisses Gautam Adani Criminal Charges 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
The American mass exodus to Canada amid Trump 2.0 has yet to materialize 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
